Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Merlini

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Blood|June 25, 1999
Prothrombotic genetic risk factors in young survivors of myocardial infarctionD Ardissino, P M Mannucci, P A Merlini, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|September 9, 2000
In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectorisP A Merlini, D Ardissino, R D Rosenberg, et al.
Journal of the American Heart Association|July 20, 2016
Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50Stephen K Kidd, Marc P Bonaca, Eugene Braunwald, et al.
Circulation|July 22, 2016
Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial InfarctionErin A Bohula, Marc P Bonaca, Eugene Braunwald, et al.
Lancet (London, England)|August 31, 2012
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trialBenjamin M Scirica, Marc P Bonaca, Eugene Braunwald, et al.
ESMO Open|August 5, 2021
Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world studyM Nannini, A Rizzo, M C Nigro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2025
Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma GroupL D'Ambrosio, A Merlini, A Brunello, et al.
Circulation Research|May 17, 2017
Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart DiseaseAkihiro Nomura, Hong-Hee Won, Amit V Khera, et al.
The New England Journal of Medicine|November 13, 2014
Inactivating mutations in NPC1L1 and protection from coronary heart disease, Nathan O Stitziel, Hong-Hee Won, et al.
The New England Journal of Medicine|March 3, 2016
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease, Nathan O Stitziel, Kathleen E Stirrups, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Blood|June 25, 1999
Prothrombotic genetic risk factors in young survivors of myocardial infarctionD Ardissino, P M Mannucci, P A Merlini, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|September 9, 2000
In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectorisP A Merlini, D Ardissino, R D Rosenberg, et al.
Journal of the American Heart Association|July 20, 2016
Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50Stephen K Kidd, Marc P Bonaca, Eugene Braunwald, et al.
Circulation|July 22, 2016
Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial InfarctionErin A Bohula, Marc P Bonaca, Eugene Braunwald, et al.
Lancet (London, England)|August 31, 2012
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trialBenjamin M Scirica, Marc P Bonaca, Eugene Braunwald, et al.
ESMO Open|August 5, 2021
Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world studyM Nannini, A Rizzo, M C Nigro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2025
Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma GroupL D'Ambrosio, A Merlini, A Brunello, et al.
Circulation Research|May 17, 2017
Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart DiseaseAkihiro Nomura, Hong-Hee Won, Amit V Khera, et al.
The New England Journal of Medicine|November 13, 2014
Inactivating mutations in NPC1L1 and protection from coronary heart disease, Nathan O Stitziel, Hong-Hee Won, et al.
The New England Journal of Medicine|March 3, 2016
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease, Nathan O Stitziel, Kathleen E Stirrups, et al.
Pageof 9